The involvement of RAS/PI3K signalling cascade was confirmed owing to the reduction in EXO1 expression upon treatment with PI3K/AKT inhibitor LY-294002 in the breast cancer cell line MDA-MB-468 (Figure 4D). Here, PIK3CA is linked to breast carcinoma.